

## P-22

### THE ACUTE TOXICITY TEST OF A NOVEL MICELLAR SOLUBILIZER FOR USE WITH INJECTABLE ANTICANCER AGENTS

Kim YW, Min KN, Pang SR, Ok KE, <sup>1</sup>Lee MJ, <sup>1</sup>Kim JJ and Sheen YY  
College of Pharmacy, Ewha Womans University, Seoul, 120-750, Korea  
<sup>1</sup>College of medicine, Seoul National University, Seoul, 151-742, Korea

The commercially available paclitaxel product, Taxol<sup>®</sup> is currently formulated in a vehicle containing approximately a 1:1 v/v mixture of polyoxyethylated castor oil (Cremophor EL) and ethanol. Cremophor EL, a commonly used surfactant for lipophilic compounds, has been associated with many issues, such as adverse effects particularly following rapid administration, stability with the possibility for drug precipitation upon dilution, and filtering requirements. It is thus apparent that there is a need for new surfactant of paclitaxel that are efficacious and less toxic than the commercial product. We have tried to develop such a new surfactant for paclitaxel, and performed the hemolysis test for chemicals which passed the paclitaxel-stabilizing test. 5 Chemicals showing relatively low hemolytic effects were tested for a single dosing toxicity test. LD50 for these chemicals were not achieved even at the maximal administrable dose, 5ml/Kg, at which Cremophor EL reached LD50. According to data based on body weight, mortality, dissection, hemological test, and biochemical test, these chemicals exhibited much more reduced toxicity than Cremophor EL. [This study has been supported by the MHW.]